CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
Conditions:   Kidney Transplant; Complications;   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin10Mg Tab;   Drug: Placebo
Sponsor:   Duke University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 29, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments